5′-O-Acetoacetyl Diacetyluridine for Oral Uridine Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Oral delivery of uridine is limited by poor bioavailability, with existing ester prodrugs like uridine triacetate providing only moderate improvement, necessitating large doses for therapeutic applications and requiring enhancements for more effective delivery and therapeutic benefits.
Innovation Solution
The introduction of an acetoacetyl substituent at the 5′ position in 2′,3′-di-O-acetyluridine enhances bioavailability and delivers uridine into circulation, concurrently providing therapeutic benefits through the co-delivery of acetoacetate, which converts to beta-hydroxybutyrate, addressing mitochondrial energy deficiencies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral uridine is administered directly, then the administration is simple, but the bioavailability is poor (approximately 7%)
Solution Approach 1:
The patent applies preliminary action by pre-modifying uridine with ester groups (acetyl or acetoacetyl) at specific positions (2′,3′-di-O-acetyl or 5′-O-acetoacetyl-2′,3′-di-O-acetyl) before administration. These pre-installed ester groups serve as absorption enhancers that are rapidly removed by nonspecific esterase activity in the body, thereby improving bioavailability without complicating the administration process.
2Reliability
If uridine triacetate is used to improve bioavailability, then absorption is enhanced, but the dose required is still large and no additional therapeutic benefit is provided
Solution Approach 1:
The patent applies multi-functionality by designing a molecule that simultaneously serves as a uridine delivery vehicle and a source of additional therapeutic compounds. The 5′-O-acetoacetyl group not only enhances absorption but also provides acetoacetate upon metabolism, which converts to beta-hydroxybutyrate for mitochondrial energy support. This dual functionality allows lower doses to achieve both delivery and therapeutic effects.
Solution Approach 2:
The patent merges uridine delivery with acetoacetate delivery into a single molecular entity. The 5′-O-acetoacetyl-2′,3′-di-O-acetyluridine molecule combines the uridine core with the acetoacetyl substituent, enabling concurrent delivery of both uridine and acetoacetate (which metabolizes to beta-hydroxybutyrate) to address multiple aspects of mitochondrial energy failure simultaneously.
3Reliability
If larger doses of uridine are administered to compensate for poor bioavailability, then sufficient uridine can be delivered, but the treatment complexity and potential side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of uridine through esterification at specific positions (2′,3′-di-O-acetyl or 5′-O-acetoacetyl-2′,3′-di-O-acetyl). These structural parameter changes enhance the molecule's absorption properties and metabolic profile, allowing effective uridine delivery at lower doses with reduced treatment complexity and fewer side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound 5′-O-(acetoacetyl)-2′,3′-di-O-acetyluridine achieves improved uridine delivery and concurrent acetoacetate delivery, offering dual therapeutic activity and mitigating mitochondrial energy failure and related disorders.
Implementation Method 1
The acetate substituents improve absorption from the gastrointestinal tract into the circulation, and are rapidly removed by nonspecific esterase activity.
Implementation Method 2
concurrently providing therapeutic benefits through the co-delivery of acetoacetate, which converts to beta-hydroxybutyrate, addressing mitochondrial energy deficiencies.
Data Source
AI summary
5′-O-(Acetoacetyl)-2′,3′-di-O-acetyluridine is useful in the treatment or prevention of disorders characterized by cerebral metabolic energy failure or diminished mitochondrial energy reserve capacity.